Xue, Mei
Mayo Clinic
Health Economics and Outcomes Research, BeOne Medicines Ltd., San Carlos, CA, USA.
Citations 2
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
Shadman, Mazyar, ChananâKhan, Asher , Campbell, David , Xue, Mei, Massoudi, Marjan , Williams, Rhys, Yang, Keri, Tam, Constantine S., Tam, Constantine S. , Shadman, Mazyar , Shadman, Mazyar , Xue, Mei , Tam, Constantine S , Williams, Rhys
Future Oncology | January 31, 2026 | Volume: 22 | Issue: 3 | Pages: 339-348
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)
Challagulla, Swetha, Pilon, Dominic , Meng, Yan, Xue, Mei, Chen, Zhuo, Wang, Yuxi, Yang, Keri, Xue, Mei , Ailawadhi, Sikander , Totev, Todor
Expert Review of Hematology | January 13, 2026 | Volume: 19 | Issue: 3 | Pages: 321-331